Barnett B, Arakelian M, Beebe D, Ontko J, Riegal C, Siu W
Psychedelic Med (New Rochelle). 2025; 2(1):1-9.
PMID: 40051760
PMC: 11658671.
DOI: 10.1089/psymed.2023.0036.
Torrado Pacheco A, Moghaddam B
J Clin Invest. 2025; 134(12).
PMID: 40047885
PMC: 11178541.
DOI: 10.1172/JCI180217.
Myran D, Xiao J, Fabiano N, Pugliese M, Kaster T, Rosenblat J
CMAJ. 2025; 197(8):E204-E213.
PMID: 40032291
PMC: 11879370.
DOI: 10.1503/cmaj.241191.
Hogea L, Tabugan D, Costea I, Albai O, Nussbaum L, Cojocaru A
Medicina (Kaunas). 2025; 61(2).
PMID: 40005395
PMC: 11857248.
DOI: 10.3390/medicina61020278.
Villiger D
Int Rev Psychiatry. 2025; 36(8):869-878.
PMID: 39980214
PMC: 11854054.
DOI: 10.1080/09540261.2024.2357669.
Cardiovascular effects and safety of classic psychedelics.
Nahlawi A, Ptaszek L, Ruskin J
Nat Cardiovasc Res. 2025; 4(2):131-144.
PMID: 39910289
DOI: 10.1038/s44161-025-00608-2.
Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation.
Irrmischer M, Puxty D, Yildirim B, Deijen J, Engelbregt H
Psychopharmacology (Berl). 2025; 242(4):725-740.
PMID: 39775022
PMC: 11890248.
DOI: 10.1007/s00213-024-06733-3.
Psychedelic Research for Alcohol Use Disorder with Comorbid Major Depressive Disorder: An Unmet Need.
de Jonge D, van der Meer P, Kramers C, Schellekens A
Curr Psychiatry Rep. 2024; 26(12):832-842.
PMID: 39612154
DOI: 10.1007/s11920-024-01567-4.
Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.
Valdez T, Patel V, Senesombath N, Hatahet-Donovan Z, Hornick M
Pharmaceuticals (Basel). 2024; 17(11).
PMID: 39598395
PMC: 11597566.
DOI: 10.3390/ph17111484.
Survey of Massachusetts peer recovery coaches' attitudes toward the use of psychedelics to treat substance use disorders.
Szpak V, Kim A, Sager Z, Suzuki J
Addict Sci Clin Pract. 2024; 19(1):86.
PMID: 39587692
PMC: 11587772.
DOI: 10.1186/s13722-024-00517-y.
The Psychedelic Renaissance: A Catholic Perspective.
Carroll T
Linacre Q. 2024; :00243639241274818.
PMID: 39544399
PMC: 11559537.
DOI: 10.1177/00243639241274818.
Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder.
Myran D, Pugliese M, Xiao J, Kaster T, Husain M, Anderson K
JAMA Psychiatry. 2024; 82(2):142-150.
PMID: 39535804
PMC: 11561722.
DOI: 10.1001/jamapsychiatry.2024.3532.
Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol.
Butler M, Bird C, Maggio C, Durden A, Modlin N, Campbell-Coker K
Wellcome Open Res. 2024; 9:401.
PMID: 39372842
PMC: 11450546.
DOI: 10.12688/wellcomeopenres.22543.1.
History, Hype, and Responsible Psychedelic Medicine: A Qualitative Study of Psychedelic Researchers.
Barber M, Gardner J, Carter A
J Bioeth Inq. 2024; .
PMID: 39365395
DOI: 10.1007/s11673-024-10386-4.
Psychedelics: From Cave Art to 21st-Century Medicine for Addiction.
Vamvakopoulou I, Nutt D
Eur Addict Res. 2024; 30(5):302-320.
PMID: 39321788
PMC: 11527458.
DOI: 10.1159/000540062.
Psychedelics and schizophrenia: a double-edged sword.
Sapienza J, Martini F, Comai S, Cavallaro R, Spangaro M, De Gregorio D
Mol Psychiatry. 2024; 30(2):679-692.
PMID: 39294303
DOI: 10.1038/s41380-024-02743-x.
Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money.
Humphreys K, Korthuis P, Stjepanovic D, Hall W
Annu Rev Psychol. 2024; 76(1):143-165.
PMID: 39094057
PMC: 11890197.
DOI: 10.1146/annurev-psych-020124-023532.
Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.
Gomez-Escolar A, Folch-Sanchez D, Stefaniuk J, Swithenbank Z, Nisa A, Braddick F
CNS Drugs. 2024; 38(10):771-789.
PMID: 39033264
DOI: 10.1007/s40263-024-01101-3.
Effects of psychedelic, DOI, on nucleus accumbens dopamine signaling to predictable rewards and cues in rats.
Martin D, Delgado A, Calu D
Neuropsychopharmacology. 2024; 49(12):1925-1933.
PMID: 38971932
PMC: 11473690.
DOI: 10.1038/s41386-024-01912-4.
Glutamate-Mediated Excitotoxicity in the Pathogenesis and Treatment of Neurodevelopmental and Adult Mental Disorders.
Nicosia N, Giovenzana M, Misztak P, Mingardi J, Musazzi L
Int J Mol Sci. 2024; 25(12).
PMID: 38928227
PMC: 11203689.
DOI: 10.3390/ijms25126521.